Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction
We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent V
| Condition(s) | Diaphragm Injury |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | We intend, with this study, to prove that blocking the molecular mechanisms whose blockade prevents VIDD in animals, will indeed prevent the development of VIDD in humans as well. We believe that this evidence will serve as the required basis for proceeding with large, ICU-based clinical trial(s) of a drug to prevent VIDD. |
| Who can participate | Inclusion Criteria: * Patients undergoing esophagectomy Exclusion Criteria: * Patients with more than mild pulmonary dysfunction * Patients with any neuromuscular disease that might compromise diaphragm function * Patients with abnormal liver or kidney function * Patients taking any immunosuppressant medication (including prednisone) or antifungal medications * History of tuberculosis * Weight loss of \>5% of body weight over previous 6 months * Pregnancy |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Stanford University |
| Locations | Stanford, California, United States |
| Start date | 2019-09-03 |
| NCT ID | NCT03681275 |
| Official listing | https://clinicaltrials.gov/study/NCT03681275 |